On Monday, October 27 2025, Envoy Medical, Inc. (NASDAQ: COCH) announced that the Nasdaq Hearings Panel granted the company a positive listing determination, allowing it to continue trading on the Nasdaq Stock Market. The panel’s decision was based on the company’s recent equity capital raises and debt extinguishment, which together substantially increased its stockholders’ equity, as well as the FDA’s approval of the company’s advancement to the final stage of the fully implanted Acclaim® cochlear implant clinical trial.
The announcement noted that Envoy now has more than 28 million shares outstanding and that trading volume has noticeably increased since the trial expansion announcement. The panel granted the company until February 23 2026 to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2), providing a clear deadline for the company to meet all remaining listing requirements.
This regulatory approval is significant for investors because it preserves the company’s access to capital markets and maintains investor confidence in its ability to meet Nasdaq’s listing standards. Envoy will continue to provide timely updates to Nasdaq and the public regarding its compliance progress, ensuring transparency as it works toward full compliance by the February deadline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.